Wells Fargo analyst Mohit Bansal raised the firm’s price target on Merck to $125 from $115 and keeps an Equal Weight rating on the shares. The firm believes Merck could guide slightly ahead of cons on top line of $63.8B as key products, Keytruda and Gardasil, may grow at mid-teens rate in 2024. However, Wells anticipates in-line EPS guide of about $8.47 due to deals and advancing pipeline driving higher expenses.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRK:
- TipRanks’ All-Star Analyst – Who is the Best on MRK Stock?
- GLP-1 Anti-Obesity Drugs: Slim Waistlines, Fat Profits
- Merck price target raised to $135 from $130 at Barclays
- Senate Health, Education, Labor & Pensions Committee holds an executive session
- Adagene falls after presenting interim results from study of ADG126